Biodexa Pharmaceuticals Adds New Phase 1 Ready Candidate To Its Portfolio To Treat Gastrointestinal Stromal Tumors

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatment of rare diseases with an increasing focus on products to treat or prevent gastrointestinal cancers, has added a new Phase 1 ready candidate to its portfolio, this time to target gastrointestinal stromal tumors, or GIST.

Several drugs are available to treat GIST, but all ultimately fail when the tumor develops resistance. When that occurs, median overall survival drops to less than a year. The value and hope of a better drug is at least partially evidenced by the eye-popping $1 billion GSK paid last year for a Phase 1 candidate, even though it shares the same mechanism of action as the currently approved drugs.